Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.

Skip to main content

Table 3 Cost-utility results

From: Cost-utility analysis of genomic profiling in early breast cancer in Colombia

 

Chemotherapy (ChT)

Oncotype DX™ (ODX)

Mammaprint™ (MMP)

LY

4.36

4.33

4.34

QALY

3.75

3.81

3.79

Costs

$13,446

$11,071

$12,892

Incremental LY

 Test vs. ChT

 

− 0.03

− 0.02

 ODX vs. MMP

 

− 0.01

 

Incremental QALY

 Test vs. ChT

 

0.06

0.03

 ODX vs. MMP

 

0.03

 

Incremental cost

 Test vs. QT

 

− $2375

− $554

 ODX vs. MMP

 

− $1821

 

ICUR (per QALY)

 Test vs. QT

 

Dominant

Dominant

 ODX vs. MMP

 

Dominant

 

Incremental NMB (per QALY)

 Test vs. ChT

 

$2751

$755

 ODX vs. MMP

 

$1996

 
  1. LY life-year, QALY quality-adjusted life-year, ICUR incremental cost-utility ratio, NMB net monetary benefit